Those data demonstrate that inhibition of MAPK activity does little to enhance the killing capacity of doxorubicin and/or paclitaxel in DU145 cells.
These data confirm the data from previous studies and strongly suggest that activation of the Raf/MEK/ERK signaling cascade does not increase drug resistance in CaP cells.